Materias dentro de su búsqueda.
Mostrando 121 - 140 Resultados de 1,014 Para Buscar '"Shareholder"', tiempo de consulta: 0.23s Limitar resultados
  1. 121
    “…Seasonal influenza efficacy [Image: see text] DISCLOSURES: James Levin, PhD, Cidara Therapeutics (Shareholder) Karin Amundson, BSc, Cidara Therapeutics (Shareholder) Allen Borchardt, PhD, Cidara Therapeutics (Employee) Thanh Lam, PhD, Cidara Therapeutics (Shareholder) Tom Brady, PhD, Cidara Therapeutics (Shareholder) Alain Noncovich, PhD, Cidara Therapeutics (Shareholder) Les Tari, PhD, Cidara Therapeutics (Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    159. efficacy of CD377, a Novel Antiviral Fc-conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models
  2. 122
    “…(Employee, Shareholder) Steve Rittenhouse, PhD, GlaxoSmithKline (Employee, Shareholder) Jianzhong Huang, PhD, GlaxoSmithKline (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1249. Genetic Evidence That Gepotidacin Shows Well-balanced Dual Targeting against DNA Gyrase And Topoisomerase IV in Neisseria gonorrhoeae
  3. 123
    “…Hoffmann-La Roche Ltd (Shareholder)Genentech, Inc. (Employee)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    322. Risk Factors for COVID-19 Disease Severity Using Electronic-Health Records in a Real-World Cohort in the United States
  4. 124
    “…O’Brien, PhD, Seres Therapeutics (Employee, Shareholder) Jessica Byrant, PhD, Seres Therapeutics (Employee, Shareholder) Mary-Jane Lombardo, PhD, Seres Therapeutics (Employee, Shareholder) Christopher Ford, PhD, Seres Therapeutics (Employee, Shareholder) Matt Henn, PhD, Seres Therapeutics (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    130. Design and Preclinical Characterization of SER-155, an Investigational Cultivated Microbiome Therapeutic to Restore Colonization Resistance and Prevent Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
  5. 125
    “…DISCLOSURES: Danny Antaki, PhD, Twist Bioscience (Employee, Shareholder) Mara Couto-Rodriguez, MS, Biotia (Employee) Kristin Butcher, MS, Twist Bioscience (Employee, Shareholder) Esteban Toro, PhD, Twist Bioscience (Employee) Bryan Höglund, BS, Twist Bioscience (Employee, Shareholder) Xavier O. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    368. Performance Characteristics of Sequencing Assays for Identification of the SARS-CoV-2 Viral Genome
  6. 126
    “…Barthel, GlaxoSmithKline: Employee and Shareholder, Salary; J. Koteff, ViiV Healthcare: Employee and Shareholder, Salary; C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Patient Experience and Views on Antiretroviral Treatment—Findings from the Positive Perspectives Survey
  7. 127
    “…DISCLOSURES: Hassen Kared, PhD, ImmunoScape (Shareholder) Alessandra Nardin, DvM, ImmunoScape (Shareholder) Hermi Sumatoh, BSc, Dip MTech, ImmunoScape (Shareholder) Faris Kairi, BSc, ImmunoScape (Shareholder) Daniel Carbajo, PhD, ImmunoScape (Shareholder) Brian Abel, PhD, MBA, ImmunoScape (Shareholder) Evan Newell, PhD, ImmunoScape (Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    LB-18. Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation
  8. 128
    “…(Employee, Shareholder) Moupali Das, MD, Gilead Sciences Inc. (Employee, Shareholder) Jared Baeten, MD, PHD, Gilead Sciences Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial
  9. 129
    “…Idania Marrero, MD, PhD, Inovio Pharmaceuticals (Employee, Shareholder) Dustin Elwood, PhD, Inovio Pharmaceuticals (Employee) Katherine Schultheis, MSc, Inovio Pharmaceuticals (Employee) Emma Reuschel, PhD, Inovio Pharmaceuticals (Employee) Trevor McMullan, MSc, Inovio (Shareholder) Patrick Pezzoli, BS, Inovio (Employee) Kimberly A. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    578. INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants
  10. 130
    “…Bakshi, GlaxoSmithKline: Employee and Shareholder, Salary; A. Tenorio, ViiV Healthcare: Employee and Shareholder, Salary; C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
  11. 131
    “…Bakshi, GlaxoSmithKline: Employee and Shareholder, Salary; A. Tenorio, ViiV Healthcare: Employee and Shareholder, Salary; C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
  12. 132
    “…Swerdlow, Pfizer Inc.: Employee and Shareholder, Salary. L. J. York, Pfizer, Inc.: Employee and Shareholder, Salary and Stock and Stock Options. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2455. Is Category B Working? Uptake Patterns of Meningococcal Group B Vaccine Among US Adolescents and Young Adults
  13. 133
    “…(Employee, Shareholder) David Magnuson, PharmD, Gilead Sciences Inc (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    855. Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States
  14. 134
    “…DISCLOSURES: Paula Peyrani, MD, Pfizer Inc (Employee, Shareholder) Chris Webber, MD, Pfizer Inc (Employee, Shareholder) Cindy Burman, PharmD, Pfizer Inc (Employee, Shareholder) Paul Balmer, PhD, Pfizer Inc (Employee, Shareholder) John L. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents
  15. 135
    “…DISCLOSURES: Jeffrey Meisner, PhD, Kaleido Biosciences (Employee, Shareholder) Jackson Lee, PhD, Kaleido Biosciences (Employee, Shareholder) Jonathan Lawrence, PhD, Kaleido Biosciences (Employee, Shareholder) Megan Roed, BA, Kaleido Biosciences (Employee, Shareholder) Johan van Hylckama Vlieg, PhD, Kaleido Biosciences (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1208. Development of a Novel Synthetic Glycan to Prevent Bacterial Infections and Ameliorate Respiratory Viral Infections
  16. 136
    “…Jansen, PhD, Pfizer (Employee, Shareholder) William C. Gruber, MD, Pfizer (Employee, Shareholder) Daniel Scott, MD, Pfizer (Employee, Shareholder) Wendy Watson, MD, Pfizer (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States
  17. 137
    “…Data on return measures (i.e., net profit margin, return on equity, total shareholder return) and risk measures (i.e., volatility of total shareholder return, beta) were derived from Bloomberg over the 2004–2016 period. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries
  18. 138
    “…STUDY FUNDING: GSK & VIR; NCT04545060 DISCLOSURES: Jaynier Moya, MD, VIR Biotechnology (Other Financial or Material Support, Jaynier Moya received non-financial support for serving as a clinical trial investigator for Vir Biotechnology) Diego Rodrigues Falci, MD, MSc, PhD, Gilead Sciences (Grant/Research Support, Scientific Research Study Investigator, Speaker's Bureau)GSK (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member)MSD (Speaker's Bureau)Pfizer (Speaker's Bureau)United Medical (Speaker's Bureau, Other Financial or Material Support) Joel Solis, MD, VIR Biotechnology (Other Financial or Material Support, Joel Solis received non-financial support for serving as a clinical trial investigator for Vir Biotechnology) Hanzhe Zheng, PhD, VIR Biotechnology (Employee) Nicola Scott, MSc, GlaxoSmithKline (Employee, Shareholder) Andrea L. Cathcart, PhD, Gilead (Shareholder)VIR (Employee, Shareholder) Christy Hebner, PhD, Vir Biotechnology (Employee, Shareholder) Jennifer Sager, PhD, GSK (Other Financial or Material Support)Vir Biotechnology (Employee, Shareholder) Erik Mogalian, PharmD, PhD, Vir Biotechnology (Employee, Shareholder) Daren Austin, PhD, GlaxoSmithKline (Employee, Shareholder) Amanda Peppercorn, MD, GlaxoSmithKline (Employee) Elizabeth L. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
  19. 139
    “…Dynavax: Investigator, Research support. H. Lal, GSK: Shareholder, Salary. Pfizer: Shareholder, Salary. L. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
  20. 140
    “…Gelone, Nabriva Therapeutics: Employee, Equity, Shareholder and Salary. Achaogen: Shareholder, Equity, Shareholder. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
Herramientas de búsqueda: RSS